On April 21, 2026 GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, reported it will present additional data from both the NHS-Galleri trial and the PATHFINDER 2 study further evaluating the Galleri multi-cancer early detection (MCED) test at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago, May 29-June 2, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The NHS-Galleri trial presentation will expand on topline results announced in February 2026. The NHS-Galleri trial, the first and only randomized controlled study of an MCED test, was designed to demonstrate population-level impact through the reduction of late-stage cancer diagnosis and increased cancer detection rate within England’s National Health Service (NHS). The trial evaluated annual screening with the Galleri test in addition to standard of care screening over three years in more than 142,000 demographically representative participants aged 50 to 77, compared to standard of care screening alone.

Building on initial results presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress in October 2025, the complete PATHFINDER 2 dataset of more than 32,000 evaluable participants will be presented. Conducted under an FDA-approved investigational device exemption, PATHFINDER 2 is the largest MCED interventional study in North America in an intended-use population with no clinical suspicion of cancer.

"The goal of cancer screening is to detect cancer before it becomes advanced or spreads, when treatment options may be broader, care and cost may be less intensive, and the opportunity for cure is often greater. Yet the status quo still leaves too many cancers unscreened. In the U.S., more than 70 percent of cancer deaths are from cancers without recommended screening tests," said Josh Ofman, MD, MSHS, President of GRAIL. "These results from NHS-Galleri and PATHFINDER 2, two large, rigorous studies, underscore Galleri’s strong performance, ability to shift detection of cancers earlier before metastatic disease, and strong safety profile. We look forward to sharing these findings, which strengthen the body of evidence supporting the clinical utility, performance, and safety of Galleri in intended-use populations and reflect GRAIL’s extensive experience building a robust evidence base for multi-cancer early detection."

ASCO Presentations

Title: NHS-Galleri: Primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection (MCED) test in population screening

Abstract Number: LBA100
Session Title: Clinical Science Symposium – ctDNA in Clinical Practice: From Detection to Clinical Decision-Making
Presentation type: Oral Presentation
Date/Time: Saturday, May 30, 2026 – 8:12-8:24 am CDT

Title: Safety and performance results from PATHFINDER 2 (PF2), a registrational study of a multi-cancer early detection (MCED) test in an intended-use population

Abstract Number: LBA10509
Session Title: Rapid Oral Abstract Session – Prevention, Risk Reduction, and Genetics
Presentation type: Oral Presentation
Date/Time: May 31, 2026 – 9:45-9:52 am CDT

Title: Implementation of a multi-cancer early detection (MCED) test in a private practice: adoption, performance, and repeat-testing patterns

Abstract Number: 10532
Presentation Type: Poster #493
Date/Time: June 1, 2026 – 1:30-4:30 pm CDT

(Press release, Grail, APR 21, 2026, View Source [SID1234664634])